ncRNA的一些简介.docxVIP

Prognostic?serum?miRNA?biomarkers?associated?with?Alzheimers?disease?shows?concordance?withneuropsychological?and?neuroimaging?assessment.Cheng L1,?Doecke JD2,?Sharples RA1,?Villemagne VL3,?Fowler CJ4,?Rembach A4,?Martins RN5,?Rowe CC6,?Macaulay SL7,?Masters CL4,?Hill AF1.Author informationAbstractThere is no consensus for a blood-based test for the early diagnosis of?Alzheimers?disease?(AD). Expression profiling of small non-coding RNAs, microRNA (miRNA), has revealed diagnostic potential in human diseases. Circulating?miRNA?are found in small vesicles known as exosomes within biological fluids such as human?serum. The aim of this work was to determine a set of differential exosomal?miRNA?biomarkers?between healthy and AD patients, which may aid in diagnosis. Using next-generation deep sequencing, we profiled exosomal?miRNA?from?serum?(N=49) collected from the Australian Imaging,?Biomarkers?and Lifestyle Flagship Study (AIBL). Sequencing results were validated using quantitative reverse transcription PCR (qRT-PCR; N=60), with predictions performed using the Random Forest method. Additional risk factors collected during the 4.5-year AIBL Study including clinical, medical and cognitive assessments, and amyloid?neuroimaging?with positron emission tomography were assessed. An AD-specific 16-miRNA?signature was selected and adding established risk factors including age, sex and apolipoprotein?4 (APOE ?4) allele status to the panel of deregulated?miRNA?resulted in a sensitivity and specificity of 87% and 77%, respectively, for predicting AD. Furthermore, amyloid?neuroimaginginformation for those healthy control subjects incorrectly classified with AD-suggested progression in these participants towards AD. These data suggest that an exosomal?miRNA?signature may have potential to be developed as a suitable peripheral screening tool for AD.Molecular Psychiatry advance online publication, 28 October 2014; doi:10.1038/mp.2014.127.有用于基于血液的测试的早期诊断没有共识阿尔茨海默氏?病（AD）。小非编码RNA的表达谱，微小